Research programme · FAT → BLOOD

BLOOD REBUILD™

Research Use Only · Not for Clinical Use

BLOOD REBUILD is the commercial-facing research output of our FAT → BLOOD programme: adipose-derived human cells programmed toward hematopoietic progenitor-like states.

Current maturity: strong preclinical proof-of-concept

Supported by human phenotype and lineage-associated differentiation data and mouse in-vivo hematopoietic contribution evidence. Definitive human LT-HSC identity, reproducibility and clinical utility remain to be established.

What the reviewed evidence demonstrates

• Conversion route. A defined workflow converts adipose-derived mesenchymal stem cells toward hematopoietic states, without introducing exogenous genes (patent-described).
• Human HSPC-associated phenotype. Converted human cells are reported positive for CD34, CD90 and CD49f.
• Lineage-associated output. Erythroid-associated differentiation (CD235a, fetal-Hb) reported after differentiation conditions; partial.
• Mouse in-vivo contribution. Donor-derived hematopoietic output detected after transplantation - meaningful supporting evidence, not definitive proof.

What comes next

The programme's proof-building now focuses on three questions: Identity - what exactly did we make; Repeatability - does it work across donors, batches and operators; Function - what can the output actually do. We are not spending the next cycle merely re-proving that the phenomenon exists.

What it is not

BLOOD REBUILD is not a therapy, not a blood product, and not available for any clinical, transfusion or diagnostic use. Marker positivity is not functional HSC identity, and no clinical efficacy has been shown. See Evidence & status.